Compare Stocks → “Retirement Secret” Showed 995% Gain Last Time We Shared It (From Stansberry Research) (Ad) Compare stocks and their fundamentals, performance, price, and technicals. Use this free stock comparison tool to evaluate companies based on their analyst ratings, book value, debt, dividend, MarketRank, news sentiment, price performance, profitability, and more. Enter up to ten stock symbols separated by a comma or space (ex. BAC, JPM, WFC, C, GS). Comparison Ideas Agriculture StocksAirline StocksApparel StocksArtificial Intelligence StocksAutomotive StocksBank StocksBitcoin StocksBlockchain StocksCanadian StocksCannabis StocksCasino StocksChatGPT StocksChinese StocksCloud Storage StocksCoronavirus Therapeutics StocksCryptocurrency StocksCybersecurity StocksDefense StocksDividend StocksDow 30 StocksEcommerce StocksElectric Vehicles StocksEnergy StocksEntertainment StockseSports StocksEV Charging StocksFertilizer StocksGold StocksGrocery StocksGrowth StocksHealthcare StocksHigh Dividend StocksHome Office StocksHotel StocksLarge Cap StocksLeisure StocksLithium StocksMagnificent Seven StocksMATANA StocksMega Cap StocksMeme StocksMetaverse StocksMid Cap StocksMining StocksMusic Industry StocksNanotechnology StocksNFT StocksOil StocksOutdoor Activities StocksPharmaceutical StocksRenewable Energy StocksRestaurant StocksRetail StocksSemiconductor StocksSocial Media StocksSolar StocksSpace StocksStay-At-Home StocksTechnology StocksTelecom StocksToy StocksUtility StocksVaccine StocksVideo Game StocksVirtual Reality StocksWallStreetBets Stocks Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare Share Comparison Share Comparison NASDAQ:GTXINASDAQ:MACKNASDAQ:MTEMNASDAQ:RGLS Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Stocks - Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeGTXIGTX$8.25-3.4%$4.77$0.74▼$25.60$198.41M2.22390,540 shs6,862 shsMACKMerrimack Pharmaceuticals$14.73+0.1%$14.71$11.53▼$15.89$214.03M1.43110,789 shs82,841 shsMTEMMolecular Templates$1.59-3.0%$2.62$1.40▼$9.45$8.54M1.1552,340 shs47,796 shsRGLSRegulus Therapeutics$2.27+2.3%$2.18$1.08▼$3.79$148.59M1.572.42 million shs97,798 shsThese 7 Stocks Will Be Magnificent in 2024With average gains of 150% since the start of 2023, now is the time to give these stocks a look and pump up your 2024 portfolio.Get This Free ReportPrice PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceGTXIGTX-3.45%-4.07%+2.43%-8.03%+2,438.46%MACKMerrimack Pharmaceuticals+0.14%+0.34%+0.07%+11.17%+21.23%MTEMMolecular Templates-3.05%+7.07%-30.57%-55.40%-73.21%RGLSRegulus Therapeutics+2.25%+2.25%-20.21%+80.16%+68.15%“Retirement Secret” Showed 995% Gain Last Time We Shared It (Ad)Central Banks Buying Gold in Record Numbers Most folks have completely missed the fact that the world's Central Banks have been quietly gobbling up as much gold as they can… Stacking it in their locked vaults on pallets in record numbers.Find out why right here (and see what you can do to get in too with just a few dollars).MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationGTXIGTXN/AN/AN/AN/AN/AN/AN/AN/AMACKMerrimack PharmaceuticalsN/AN/AN/AN/AN/AN/AN/AN/AMTEMMolecular Templates0.9265 of 5 stars0.02.00.04.60.64.20.0RGLSRegulus Therapeutics2.4313 of 5 stars4.42.00.00.02.01.70.0Analyst RatingsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceGTXIGTXN/AN/AN/AN/AMACKMerrimack PharmaceuticalsN/AN/AN/AN/AMTEMMolecular TemplatesN/AN/AN/AN/ARGLSRegulus Therapeutics2.80Moderate Buy$7.25219.38% UpsideCurrent Analyst RatingsLatest GTXI, RGLS, MTEM, and MACK Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails3/25/2024RGLSRegulus TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$9.003/19/2024RGLSRegulus TherapeuticsCanaccord Genuity GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$12.00 ➝ $11.003/18/2024RGLSRegulus TherapeuticsLeerink PartnrsSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOutperform3/18/2024RGLSRegulus TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$9.003/18/2024RGLSRegulus TherapeuticsSVB LeerinkSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageOutperform$6.003/13/2024RGLSRegulus TherapeuticsWells Fargo & CompanySubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetEqual Weight ➝ Equal Weight$2.00 ➝ $3.00(Data available from 4/26/2021 forward. View 10+ years of historical ratings with our analyst ratings screener.)Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookGTXIGTXN/AN/AN/AN/A$1.09 per shareN/AMACKMerrimack PharmaceuticalsN/AN/AN/AN/A$1.31 per shareN/AMTEMMolecular Templates$57.31M0.15N/AN/A$0.78 per share2.04RGLSRegulus TherapeuticsN/AN/AN/AN/A$1.05 per shareN/AProfitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateGTXIGTX-$38.42M-$1.65N/AN/AN/AN/A-104.19%-86.42%N/AMACKMerrimack Pharmaceuticals-$1.18M-$0.08N/A∞N/AN/A-6.24%-6.09%5/2/2024 (Estimated)MTEMMolecular Templates-$8.12M-$1.55N/AN/AN/A-14.18%-9,335.53%-20.51%5/20/2024 (Estimated)RGLSRegulus Therapeutics-$30.04M-$1.59N/AN/AN/AN/A-109.21%-80.55%5/9/2024 (Estimated)Latest GTXI, RGLS, MTEM, and MACK EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails3/29/2024Q4 2023MTEMMolecular Templates-$2.10-$0.73+$1.37-$0.73N/A$7.02 million3/21/2024Q4 2023RGLSRegulus Therapeutics-$0.40-$0.40N/A-$0.40N/AN/A3/7/2024Q4 2023MACKMerrimack PharmaceuticalsN/A-$0.01-$0.01-$0.01N/AN/ADividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthGTXIGTXN/AN/AN/AN/AN/AMACKMerrimack PharmaceuticalsN/AN/AN/AN/AN/AMTEMMolecular TemplatesN/AN/AN/AN/AN/ARGLSRegulus TherapeuticsN/AN/AN/AN/AN/ADebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioGTXIGTXN/A12.3912.39MACKMerrimack PharmaceuticalsN/A43.5043.50MTEMMolecular TemplatesN/A0.970.97RGLSRegulus TherapeuticsN/A3.313.31OwnershipInstitutional OwnershipCompanyInstitutional OwnershipGTXIGTX9.50%MACKMerrimack Pharmaceuticals63.97%MTEMMolecular Templates95.47%RGLSRegulus Therapeutics92.38%Insider OwnershipCompanyInsider OwnershipGTXIGTX40.90%MACKMerrimack Pharmaceuticals28.87%MTEMMolecular Templates18.70%RGLSRegulus Therapeutics8.41%MiscellaneousCompanyEmployeesShares OutstandingFree FloatOptionableGTXIGTX2124.05 millionN/ANot OptionableMACKMerrimack Pharmaceuticals42614.53 million10.34 millionOptionableMTEMMolecular Templates1115.37 million4.37 millionNo DataRGLSRegulus Therapeutics3065.46 million59.96 millionOptionableGTXI, RGLS, MTEM, and MACK HeadlinesSourceHeadlineRegulus Therapeutics (NASDAQ:RGLS) Shares Cross Above 200-Day Moving Average of $1.61americanbankingnews.com - April 24 at 3:44 AMRegulus Therapeutics (NASDAQ:RGLS) Research Coverage Started at StockNews.comamericanbankingnews.com - April 16 at 2:22 AMRegulus: It Is Finding Its Stride Despite Initial Setback In Targeting ADPKDseekingalpha.com - April 10 at 1:50 PMBuy Rating on Regulus’s RGLS8429 Backed by Positive Phase 1b Data and Unmet ADPKD Treatment Needsmarkets.businessinsider.com - March 28 at 2:29 PMShort Interest in Regulus Therapeutics Inc. (NASDAQ:RGLS) Expands By 9,244.3%marketbeat.com - March 27 at 10:53 AMBuy Rating Reaffirmed for Regulus Therapeutics Amid Promising Drug Development Milestonesmarkets.businessinsider.com - March 26 at 3:28 AMRegulus Therapeutics Inc (RGLS) Reports Year-End Earnings, Highlights Key Clinical Advancementsfinance.yahoo.com - March 23 at 10:30 AMRegulus Therapeutics Inc.: Regulus Therapeutics Reports Fourth Quarter and Year-End 2023 Financial Results and Recent Updatesfinanznachrichten.de - March 22 at 7:21 AMRGLS Stock Earnings: Regulus Therapeutics Misses EPS for Q4 2023investorplace.com - March 21 at 11:00 PMRegulus: Q4 Earnings Snapshottimesunion.com - March 21 at 9:20 PMRegulus Therapeutics Reports Fourth Quarter and Year-End 2023 Financial Results and Recent Updatesfinance.yahoo.com - March 21 at 4:20 PMBuy Rating Affirmed for Regulus Therapeutics on Promising RGLS8429 ADPKD Treatment Datamarkets.businessinsider.com - March 19 at 11:39 PMRGLS Mar 2024 7.500 putfinance.yahoo.com - March 15 at 5:16 AMBiotech Stock Roundup: AMLX, ACAD Down on Study Data, MRNA, RGLS Gain on Updates & Morefinance.yahoo.com - March 14 at 2:15 PM$100 million fundraise for antisense firm working in nephrologythepharmaletter.com - March 13 at 7:40 PMRegulus’s Stock RGLS: Hold Rating Amidst Promising Yet Preliminary ADPKD Study Results and Financial Positionmarkets.businessinsider.com - March 13 at 2:40 PMRegulus (RGLS) Up 71% on Topline Data from Kidney Disease Studyzacks.com - March 13 at 1:11 PMRegulus Therapeutics Shares Soar on Funding, Study Datamarketwatch.com - March 12 at 7:11 PMRegulus Surges 60% On Positive Outcome From Phase1b MAD Trial, Private Placement Of $100 Mlnmarkets.businessinsider.com - March 12 at 2:10 PMWhy Is Kidney Disease-Focused Regulus Therapeutics Stock Trading Higher On Tuesday?msn.com - March 12 at 2:10 PMRegulus cues up $100m placement on ADPKD drug datapharmaphorum.com - March 12 at 9:10 AMConsumer Prices Tick Higher in February as US Equity Futures Turn Mixed Pre-Bellmsn.com - March 12 at 9:10 AMRegulus Announces $100 Mln Private Placement, Positive Data From Phase 1b MAD Trial Of RGLS8429markets.businessinsider.com - March 12 at 9:10 AMRegulus Therapeutics Announces Oversubscribed $100 Million Private Placement of Equityprnewswire.com - March 12 at 6:32 AMNew MarketBeat Followers Over TimeMedia Sentiment Over TimeCompany DescriptionsGTXNASDAQ:GTXIGTx, Inc., a biopharmaceutical company, engages in the discovery, development, and commercialization of medicines for the treatment of stress urinary incontinence (SUI) and prostate cancer. It develops selective androgen receptor modulators (SARMs) for the treatment of breast cancer, SUI, and Duchenne muscular dystrophy; and selective androgen receptor degraders to treat progressive castration-resistant prostate cancer. The company's SARM product candidate is the enobosarm GTx-024, a Phase II proof-of-concept clinical trial for patients with androgen receptor (AR) positive triple-negative breast cancer; and estrogen receptor positive and AR positive advanced breast cancer, as well as postmenopausal women with SUI. GTx, Inc. was founded in 1997 and is headquartered in Memphis, Tennessee.Merrimack PharmaceuticalsNASDAQ:MACKMerrimack Pharmaceuticals, Inc. operates as a biopharmaceutical company in the United States. The company was incorporated in 1993 and is headquartered in Cambridge, Massachusetts.Molecular TemplatesNASDAQ:MTEMMolecular Templates, Inc., a clinical stage biopharmaceutical company, focuses on the discovery and development of biologic therapeutics for the treatment of cancer and other serious diseases in the United States. The company primarily develops therapies through its proprietary biologic engineered toxin body (ETB) drug platform. The company is developing MT- 8421, an ETB candidate that is in Phase I clinical trial for the treatment of dismantling TME through direct cell-kill of tumor and immune cell; MT-0169, which is in Phase I clinical trial to treat relapsed/refractory multiple myeloma; and MT-6402 in that is in Phase I clinical trial for relapsed/refractory patients with PD-L1 expressing tumors. The company has a collaboration agreement with Bristol Myers Squibb to discover and develop novel products containing ETBs directed to multiple targets. Molecular Templates, Inc. was founded in 2001 and is headquartered in Austin, Texas.Regulus TherapeuticsNASDAQ:RGLSRegulus Therapeutics Inc., a clinical stage biopharmaceutical company, focuses on discovery and development of drugs that targets microRNAs to treat a range of diseases in the United States. Its product candidates include RG-012, an anti-miR targeting miR-21 that is in Phase II clinical trial for the treatment of Alport syndrome, a life-threatening kidney disease; and RGLS8429, an anti-miR targeting miR-17, which is in Phase 1b clinical study for the treatment of autosomal dominant polycystic kidney disease. The company is also developing a pipeline of preclinical drug products for target organ-selective delivery strategies. Regulus Therapeutics Inc. was incorporated in 2007 and is headquartered in San Diego, California. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.